The Astrazeneca (Ap) vaccine
Vaccines, India authorizes emergency use of AstraZeneca
AstraZeneca vaccine, for Ema 'unlikely' ok EU in January
Vaccine: AstraZeneca assures: "Winning formula found. 95% effective, 100% against severe symptoms"
Share
January 04, 2021 The Serum Institute of India, the pharmaceutical company that produces the AstraZeneca vaccine in India, approved yesterday by the Asian giant, will have to give absolute priority to India for a few months and will not be able to sell the vaccine to other countries for at least three months: revealed Adar Poonawalla, chief executive of the Pune pharmaceutical company.
The veto, explained Poonawalla in an interview with the AP agency, was placed by the Delhi government as a condition for approval, in order to ensure India's priority over the first 100 million doses.
Poonawalla added that the Serum Institute, which is the largest global producer of vaccines, already has nearly 60 million vaccines ready, all destined for India, and that it will not be able to sell them to governments in other countries or market them privately until at least. in April.
India will pay 200 rupees (2.30 euros) for each dose, while, subsequently, the market price will be around 1000 rupees (12.5 euros) per dose.
The Serum Institute must therefore postpone the delivery of the other millions of doses already booked by the Covax coalition, the WHO global initiative with the international alliances Gavi and Cepi, which aims to guarantee equal access to anti-Covid-19 immunization. to less rich countries;
The Serum Institute has previously pledged to supply the Covax coalition with between 200 and 300 million doses by the end of 2021.